Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy

Amgen's $13.4 billion cash offer has won the bidding war for Celgene and Bristol-Myers Squibb's psoriasis drug, Otezla. Here's why the Goliath biopharma is betting so big on its success. Also, new data from The Medicines Company suggests a new cholesterol-busting drug is on it's way to approval. Stocks: CELG, BMY, AMGN, MDCO Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Om Podcasten

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.